Effective management of major lower extremity wounds using an acellular regenerative tissue matrix: a pilot study

Orthopedics. 2004 Jan;27(1 Suppl):s145-9. doi: 10.3928/0147-7447-20040102-14.

Abstract

Wound healing is a significant problem in orthopedics. Graftjacket tissue matrix (Wright Medical Technology, Inc, Arlington, Tenn), a novel acellular regenerative tissue matrix, has been designed to aid wound closure. A prospective, randomized study was initiated to determine the efficacy of this tissue product in wound repair compared with conventional treatment. Lower extremity wounds are refractile to healing in patients with diabetes mellitus. Therefore, researchers used diabetic foot ulcers to evaluate the efficacy of GraftJacket tissue matrix in wound repair. Only a single administration of the tissue matrix was required. After 1 month of treatment, preliminary results demonstrate that this novel tissue matrix promotes faster healing at a statistically significant rate over conventional treatment. Because wounds in this series of patients are deep and circulation around the wound is poor, the preliminary results suggest that this tissue matrix will be applicable to other types of orthopedic wounds.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Aged
  • Biocompatible Materials*
  • Female
  • Humans
  • Injury Severity Score
  • Leg Injuries / therapy*
  • Male
  • Middle Aged
  • Pilot Projects
  • Prospective Studies
  • Single-Blind Method
  • Soft Tissue Injuries / therapy
  • Tissue Engineering
  • Wound Healing*

Substances

  • Biocompatible Materials